News Brexit could delay drug launches, former MHRA chief warns Britain will be in "second or third tier" of drug launches, experts warn.
Views & Analysis Pharma nervous as Brexit reckoning nears UK pharma leaders are putting a brave face on Brexit – but the ‘phoney war’ is about to give way to hard-nosed negotiations
News Could UK's post-Brexit regulator evaluate value as well? But longer-term benefits could include faster reimbursement decisions.
News With all eyes on IO, Tagrisso could be AZ's ace card AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.
News Kyowa Kirin to expand UK headquarters despite Brexit Other Japanese firms could scale back UK investment.
News Hunt under pressure over plans to quit EMA Britain could be in "second rank" of medicines access, warn MPs.
News J&J adds rare disease wAIHA to Imaavy's potential uses Johnson & Johnson's 'Swiss army knife' drug Imaavy has shown efficacy in a pivotal trial involving patients with rare autoimmune disorder wAIHA.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
